contexts of use, conditions of test subjects, and ecological variables. 6 The appeal of tDCS is its ease of application, cost, and ability to be deployed in a range of wide environments 7 (eg in-and out-patient clinics, mobile/field medical units, etc.). Importantly, in numerous controlled clinical trials, tDCS has been shown to be effective in reducing clinical features of the aforementioned conditions that are refractory to other treatments 8 (eg pharmacological agents, physical, and/or cognitive therapy, etc.). However, because clinical trials are inherently restricted in scope, time, and geography, patient access to therapy in trials is often impractical or difficult. Though there are ongoing efforts to establish rigorous methods for remotely supervised clinical trials. 9 For patients that have completed clinical trials, options for continuity of clinical care are at best limited (if not wholly unavailable), even if patients have proven to be highly responsive. In light of this, patients who may gain clinical benefit from tDCS treatment often are unable to access clinical venues for its safe and apt provision, increasing the burden of disease. If denied access to provision to tDCS under medical care, some patients will then seek alternative resources. One such avenue is the growing body of information available via the internet regarding 'do-it-yourself' (DIY) approaches, which may include adaptation of commercially available devices (eg iontophoresis) for transcranial neuromodulation.
10 Furthermore, the issues addressed here are not related to the ethico-legal concerns generated by DIY or direct-to-consumer tDCS, 11 but rather refer to consequences of denying patients supervised, well-controlled tDCS clinical care.
In sum, when considering the possible use of tDCS, it becomes important to address potential harms of both omission and commission. In the former instance, there is defined risk of incurring increased burden of illness by not engaging tDCS to treat patients in whom other interventions have been shown to be ineffective, impractical, or to produce deleterious effects. In the latter, there is theoretical risk of eliciting adverse effects by employing tDCS. We posit that more finely grained assessment of extant information available about tDCS effects and effectiveness under specific conditions and when treating particular types of patients will be essential to establish a more balanced stance toward use and non-use, and in this way ameliorate the possibility of both types of harm.
Pursuant to this goal, and with patient care ascendant, we advocate (1) that those tDCS protocols under systematic testing in clinical trials be made available, under limited conditions, in clinical care; (2) that guidelines and regulations for clinical use be focused upon and reflective of realistic assessment of all extant information available to date; (3) ongoing research-under ecologically valid, clinical conditions-be sustained and expanded to inform ongoing care decisions; so as to contribute to (4) developing an iterative, accurate and usable repository of data derived from laboratory studies and practice experiences to guide the safe and sound use of tDCS in defined clinical contexts 12 . Toward these ends, regulatory oversight will be both important and required, as this is an established protocol for both drug-and device-based interventions to be used to effect medical benefit. Pharmacological compounds are strategically validated by the producing commercial entity, and industry-sponsored research entails formulaic preclinical and clinical phases, pursuant to FDA review and ultimate approval. Yet, it is noteworthy that in the United States, a number of compounds are employed 'off-label'. In its general form, tDCS is not a proprietary technique; tDCS research is 'investigator initiated' and thus the extant corpus of completed tDCS studies-many of which appear to demonstrate positive therapeutic outcomes-are heterogeneous with regard to dose, patient selection/inclusion, adjunct treatment(s) and outcome metrics. One salient finding gained from review of these studies is that tDCS effects are relatively selective and specific, as dependent upon context of the intervention and certain neurocognitive characteristics of the subjects involved. 13 The diversity of these contexts can render it difficult for practitioners to easily and accurately assess both particular effectiveness, and broad clinical benefit with respect to defining patient selection, and treatment parameters. But the development and validation of tDCS is distinct from that conventional proprietary drugs, and so the diversity of tDCS clinical-trial designs (and so outcomes) should be understood to reflect a broad investigator-initiated (and typically government and foundation funded) effort.
At present, tDCS trials are reviewed and conducted in accordance with the 'NonSignificant-Risk' designation for medical devices.
14 Typical side effects of tDCS are temporary skin irritation and itching at the sites of electrode placement, with the incidence of other common side effects comparable to sham. 15 It is important to note that, in controlled human trials, no serious adverse effects (ADEs) of tDCS treatment have been reported after greater than 50,000 sessions of tDCS in diverse patient populations at numerous institutions. 16 The risk of tDCS is considered to be so low that routine testing is acceptable in healthy volunteers. 17 Indeed, such considerations are of equal merit when addressing and assessing relative benefits and risks of employing tDCS to treat patients suffering from severe neuropsychiatric disorders.
The official regulatory posture governing the use of tDCS is progressive, 18 with current regulation in the EU supporting the use of tDCS in the treatment of depression and pain. In most cases, the use of tDCS remains investigational or off-label therapy. In the United States, the prescribed use(s) of investigational devices remain highly regulated in compliance with FDA Quality Systems and/or IEC certification standards. When medical devices are used with the intent to treat (outside of the context of a clinical trial), FDA approval is not necessarily required. 19 However, Wexler et al., 2015 20 notes that laws regarding consumer safety and advertising still apply to these medical devices when used outside of clinical trials. We agree with Wexler et al. that clinicians currently, and could continue to repurpose iontophoresis devices for 'off-label' tDCS treatments, as such practice is legal in the United States. However, this does not, nor should not suggest cavalier use of tDCS in clinical contexts. A framework of ethical responsibilities, inquiry, and considerations important to the use of any neurotechnology has been proposed, and we advocate that this should be taken into account prior to engaging tDCS in research and practice. 21 Guidance documents on best practices continue to be updated 22 and practitioner certification available. 23 Only medical-grade devices and accessories provide adequate assurance of reliability and reproducibility in the context of clinical care.
Physicians remain obligated to obtain and employ the most current knowledge about the product (including if it is manufactured to medical device standards), and subject-specific dose and treatment profiles. 24 Such knowledge should be based upon both scientific rationale and sound medical evidence (eg clinical trials, reports of investigator-initiated research, empirical laboratory studies relevant to the focus and scope of intended use-in-practice, and evidence-based reviews), and in this light, there is an equally strong imperative to stringently maintain medical records of use,
